Stockscreener 앱 받기
21.38
0.14%
0.04
Acadia Pharmaceuticals Inc 주식(ACAD)의 최신 뉴스
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Why ACADIA Pharmaceuticals Inc. stock could be next big winner2025 Dividend Review & Entry Point Confirmation Signals - newser.com
News impact scoring models applied to ACADIA Pharmaceuticals Inc.Price Action & Reliable Volume Spike Trade Alerts - newser.com
JP Morgan Updates ACADIA Pharmaceuticals (ACAD) Analyst Rating | - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Given New $33.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Will ACADIA Pharmaceuticals Inc. rebound enough to break evenMarket Sentiment Report & Fast Entry High Yield Stock Tips - newser.com
Using R and stats models for ACADIA Pharmaceuticals Inc. forecastingWeekly Investment Report & Verified Swing Trading Watchlist - newser.com
Real time social sentiment graph for ACADIA Pharmaceuticals Inc.Insider Selling & Real-Time Stock Movement Alerts - newser.com
Acadia slumps after trial setback for Prader-Willi syndrome drug; Soleno jumps - MSN
What analysts say about ACADIA Pharmaceuticals Inc stockMomentum Stock Picks & Budget Friendly Growth - earlytimes.in
What drives ACADIA Pharmaceuticals Inc stock priceAnalyst Downgrades & Market Crushing Stock Picks - Early Times
What machine learning models say about ACADIA Pharmaceuticals Inc.Index Update & Long-Term Growth Plans - newser.com
Detecting price anomalies in ACADIA Pharmaceuticals Inc. with AIInsider Selling & Stepwise Trade Execution Plans - newser.com
Using flow based indicators on ACADIA Pharmaceuticals Inc.2025 Technical Patterns & Risk Controlled Swing Alerts - newser.com
Acadia drops development of carbetocin in PWS - The Pharma Letter
Acadia to stop development of rare disease therapy after trial failure - ET Pharma
ACADIA Pharmaceuticals Hits Day Low of $20.03 Amid Price Pressure - Markets Mojo
Acadia Pharmaceuticals stock price target maintained by BMO after trial miss - Investing.com Canada
ACAD Stock Down 10% Following Phase III Hyperphagia Study Failure - sharewise.com
Acadia Pharmaceuticals Hit by Trial Failure for Prader-Willi Syndrome, Deutsche Bank Says - MarketScreener
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $35 - 富途牛牛
Deutsche Bank Adjusts ACADIA Pharmaceuticals Price Target to $29 From $35, Maintains Buy Rating - MarketScreener
Acadia, Harmony record late-stage rare disease failures - pharmaphorum
Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint - BioSpace
Acadia Pharmaceuticals stock price target lowered to $35 at TD Cowen - Investing.com
Acadia Gives Up In PWS After Another ACP-101 Phase III Miss - insights.citeline.com
Oppenheimer cuts Acadia Pharmaceuticals stock price target after failed study By Investing.com - Investing.com UK
Biotech Stocks Diverge As Genetic Disease Drug Fails - Investor's Business Daily
Acadia grounds Prader-Willi candidate after trial failure, leaving the market to Soleno - Fierce Pharma
Acadia Pharmaceuticals: Reeling After PWS FailureDowngrading To Hold (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint By Investing.com - Investing.com Canada
Acadia Pharma Tumbles On Failed Genetic Disease Drug; Soleno Surges - MSN
BMO Capital reiterates Acadia Pharmaceuticals stock rating despite trial failure - Investing.com Canada
Oversold Conditions For Acadia Pharmaceuticals (ACAD) - Nasdaq
ACAD: Latest Developments and Market Insights - GuruFocus
Acadia Pharmaceuticals (ACAD) Faces Setback After Phase 3 Trial Results - GuruFocus
ACADIA Pharmaceuticals (ACAD): Needham Lowers Price Target, Maintains Buy Rating | ACAD Stock News - GuruFocus
ACADIA Pharmaceuticals (NASDAQ:ACAD) Shares Gap Down Following Analyst Downgrade - MarketBeat
Acadia to scrap Prader-Willi drug after study setback - BioPharma Dive
Acadia Pharmaceuticals stock drops after ACP-101 misses endpoint - Investing.com
Needham & Company LLC Has Lowered Expectations for ACADIA Pharmaceuticals (NASDAQ:ACAD) Stock Price - MarketBeat
Acadia Pharmaceuticals stock unchanged as BofA maintains Neutral rating By Investing.com - Investing.com UK
Acadia, with a failed phase III, drops Prader-Willi candidate - BioWorld MedTech
Acadia’s phase 3 trial for Prader-Willi syndrome drug fails to meet goals - Investing.com Australia
Traders Buy Large Volume of ACADIA Pharmaceuticals Call Options (NASDAQ:ACAD) - MarketBeat
Acadia Pharmaceuticals (ACAD) Experiences Significant Drop in St - GuruFocus
Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target - TipRanks
Leerink on Acadia (ACAD): 'Despite the news, we still like the stock' - StreetInsider
Acadia Scraps Prader-Willi Drug After Late-Stage Failure - BioSpace
Acadia Pharma Faces Trial Setback As Prader-Willi Syndrome Trial Falls Short - Benzinga
Acadia Pharmaceuticals (ACAD) Shares Dip After Trial Disappointm - GuruFocus
Lithium Americas, Oracle, Acadia Pharma: Trending Tickers - Yahoo Finance
Acadia Pharma (ACAD) Shares Plunge After Prader-Willi Drug Setba - GuruFocus
Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure By Investing.com - Investing.com South Africa
ACAD Stock Falls as Phase 3 Trial Results Disappoint - GuruFocus
Stifel maintains Hold rating on Acadia Pharmaceuticals stock after drug failure - Investing.com
Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study - statnews.com
ACAD Faces Setback as Phase 3 Trial Fails - GuruFocus
Acadia (ACAD) Trial Results Impact Soleno Stock - GuruFocus
BMO Capital: 'expect ACAD shares to decline' - StreetInsider
Acadia Pharmaceuticals down 13% after COMPASS PWS trial misses endpoints - TipRanks
Acadia Pharmaceuticals' ACP-101 for Hyperphagia in Prader-Willi Syndrome Fails to Meet Primary Endpoint in Phase 3 Trial - MarketScreener
1.35%
0.96%
자본화:
|
볼륨(24시간):